Chris Bhatt

Chris Bhatt investigates genomic biomarkers that improve risk stratification and treatment decision-making in localized prostate cancer. His research has validated commercial genomic classifiers including Decipher and Oncotype DX in predicting prostate cancer recurrence and metastasis risk. He has integrated genomic testing with pathological and clinical features to develop improved risk models for treatment selection. His work on prospective genomic classifier-guided treatment de-escalation and escalation trials is changing how genomics informs prostate cancer management.